ERBB2 and breast carcinoma: The latest ADC, trastuzumab deruxtecan (T-DXd or DS-8201), has shown remarkable efficacy in patients with HER2-positive advanced breast cancer (Hurvitz et al., 2023; Cortés et al., 2022).